Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of PD-1 Inhibition in Recurrent HCC After Liver Transplantation
NCT03966209Phase 1Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2019
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Serious Adverse Event Rate at 1.5 years and Acute Graft Rejection Rate at 1.5 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03966209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966209.